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Background: The aim of this study was to investigate the effects and safety of 120 watt PVP surgery for the high
risk prostate hyperplasia patients.
Methods: 120 watt PVP surgery was performed on 120 cases of high risk prostate hyperplasia patients. The
assessment included the operation time, energy consumed, hemoglobin changes, and serum salt concentration,
whether to keep urinary catheter, hospitalization time, and complications after the operation. International Prostate
Symptom Scoring (IPSS), the maximum urine flow rate (Qmax) and residual urine volume (RUV) were conducted
preoperatively and postoperatively for the patients.
Results: There were 30% of patients taking oral anti-coagulant drug (n = 36), 88 cases with abnormal ECGs. All the
patient’s internal diseases, include the cardiovascular disease (42/120), the hypertension (56/120), the respiratory
system diseases (51/120), the cerebrovascular diseases (39/120), anemia (24/120), liver or kidney dysfunction
(16/120), diabetes (18/120), hypoproteinemia (15/120) were under controlled. The average age, prostate volume
and energy consumed was 82.8 ± 8.6 (70–96) years, 66.1 ± 25.3 (30–160) ml, and 224 ± 85 (31–596) kJ respectively.
The average follow-up time was 20.8 ± 3.2 (18–24) months. The incidence of bladder neck contracture and urethral
stricture were 1.7% and 0.8% respectively, no prostate cancer occurred during the subsequent follow-up period.
Conclusions: 120 watt PVP surgery can safely and effectively alleviate the urination parameters of high risk prostate
hyperplasia patients. The surgical process is safe and effective, and is not affected by the various internal diseases or
the use of oral anti-coagulant drugs.
Keywords: 120 watt green laser, Benign prostatic hyperplasia, Elderly patientsBackground
Although transurethral resection of the prostate (TURP)
and various kinds of minimally invasive surgery had be-
ing widely used for benign prostatic hyperplasia (BPH)
for many years, these treatment methods still have ser-
ious complications on patients and sometimes cases of
death still occurred postoperatively [1,2]. Because most
of these patients are old, and accompanied with many
medical complications, Gesenberg [3] believe that ap-
proximately 10%-15% of BPH patients cannot tolerate
surgical operations owing to concomitant illnesses.
These patients could only undergo non-surgical drug* Correspondence: lijunchencn@163.com
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reproduction in any medium, provided the ortreatment to maintain urination or bladder fistulization
for urinary diversion, and this seriously affected patients’
quality of life [4,5]. These elderly high risk BPH patients
have always constituted a difficult problem in terms of
clinical treatment [6]. So, finding a mini-invasive way to
reduce the operation time and bleeding during the surgery
become the most important direction of our surgeon.
Within the past 10 years, green laser system has
already developed from coagulation to incisions and
vaporization. This surgical method can not only rapidly
vaporize the prostate tissue, but also reduce surgical
complication rate to an acceptable level [7-9].
In this study we carried out the 120 watt PVP surgery
for the above-described special patients, and the longest
follow up time was 24 months. The aim of this article is
to discuss how complications associated with photoselectivetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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elderly high risk patients. In addition, recommendations
and discussion regarding minimizing complications through
modification of the new GreenLight HPS (TM) 120-W
(American Medical System Incorporation, Minnetonka,
MN, USA) laser operative technique are provided.
Methods
Patient
Between January 2009 and January 2011, a total of 120
patients with LUTS due to BPH were assessed for
eligibility to enter the study. All patients were subjected
to the standard urologic preoperative evaluation,
including history taking, clinical examination including
digital rectal examination (DRE), urine analysis, routine
blood chemistry including prostate-specific antigen
(PSA). TRUS was used to estimate the size of the pros-
tate. Urine flowery was carried out to measure Qmax.
IPSS was completed by self assessment after translation
and validation.
Inclusion criteria were patients with moderate or se-
vere LUTS (International Prostate Symptom Score
[IPSS] >16), failure of previous medical treatment with a
washout period of at least 2 wk, maximum flow rate
(Qmax) <15 ml/s, and ability to give a fully informed
consent. Exclusion criteria were patients with urethral
strictures, bladder stone, or neurogenic bladder. In case
of an elevated PSA level or abnormal digital rectal exam-
ination, at least two series of TRUS-guided prostate
biopsies were performed preoperatively to rule out pros-
tate cancer (PCa). Patients diagnosed with Pca were ex-
cluded from the study. Patients with known neurological
disorders such as multiple sclerosis, Parkinson’s disease,
or a known history of spinal cord injury were also ex-
cluded. The use of anticoagulants or indwelling urinary
catheters for urinary retention was not a criterion for
exclusion.
The patient ages were 70 to 96 years old and the aver-
age age was 82.8 ± 8.6 years old. There were 1–8 internal
diseases as the concomitant illnesses and there were 88
cases with abnormal ECGs for the complications. Of
these, there were 42 cases of cardiovascular disease, 56
cases of hypertension, 51 cases of respiratory system dis-
eases, 39 cases of cerebrovascular diseases, 24 cases of
anemia, 16 cases of liver or kidney dysfunction, 18 cases
of diabetes and 15 cases of hypoproteinemia. The aver-
age number of complications was 3.7 internal diseases.
There were 8 cases of patients with simultaneous blad-
der stones, and some of the patients had as complica-
tions fever, hypovolemia, acid–base imbalance and
hyperlipidemia, etc. A comprehensive and systematic as-
sessment was conducted for all patients, including a
digital rectal examination, urinalysis, transrectal ultra-
sound for measuring the prostate size, urinary systemexamination, serum PSA examination, etc., and IPSS
scoring was conducted prior to surgery in each case. A
prostate puncture biopsy was conducted for patients
with an abnormal PSA level or digital rectal examination
abnormalities in order to eliminate prostate cancer. The
average preoperative prostate volume was 66.1 ± 25.3
(30–160) ml, and the residual urine volume (RUV) was
(246 ± 38) ml. There were 20 cases for which bladder fis-
tulization and an indwelling catheter were performed
before the surgery, and the maximum urine flow rate
(Qmax) was 3.6-10.4 (6.2 ± 2.6) ml/s. The average Inter-
national Prostate Symptom Score (IPSS) was (26.5 ± 3.8)
points. Prior to the operation, antihypertensive and anti-
diabetic drugs were applied to lower the blood pressure
to 150/95 mmHg and under, and the blood sugar to
8.4 mmol/L and under. After those patients with kidney
failure were treated with an indwelling catheter, the
serum creatinine level was at 330 μmol/L and under,
and an assessment of the anesthesia risk was conducted
by the anesthesia department and related departments.
This study was conducted in accordance with the declar-
ation of Helsinki. This study was conducted with ap-
proval from the Ethics Committee of 307 Hospital of
PLA Written informed consent was obtained from all
participants.
Anesthesia method
Total intravenous anesthesia with a Proseal laryngeal
mask airway (Ningbo Boya Medical Equipment Co., Ltd)
was adopted, and the patients assumed the lithotomy
position. A routine multiparameter monitor monitored
the ECG, heart rate, respiration, oxygen saturation and
urine volume, and at the same monitoring of such indi-
ces as the invasive artery blood pressure, central venous
pressure, etc. was carried out. The chief medications for
induction and maintenance were Propofol, Fentanyl,
Midazolam and Vecuronium (or Atracurium).
Surgical methods
The non-contact green laser treatment system made by
Green Light Corporation (USA) was employed. The
power was 120 watts. The side firing ADD Stat™ laser
fiber with a 600 mm core diameter was placed in
the cavity with the double sheath mirror (22.5 Fr, 30°)
(Karl Storz Karl Storz GmbH & Co. KG), and physio-
logical saline was the irrigation fluid. The operation was
conducted under monitoring with a Storz camera sys-
tem, the ADD non-contact optical fiber issued red light
as the pilot light, and the distance between the optical
fiber side hole and the prostate tissue was approximately
0.5 mm (whenever hemorrhaging occurred, it can be en-
larged to 2–3 mm or the laser output power can be ad-
justed to 40 watts). The vaporization begins from the
median lobe at the bladder neck, the ADD optical fiber
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ually proceeds up to the verumontanum, place the bot-
tom part of the anterior urethra in the same plane as the
bladder trigone, and separately vaporize the lobes on
both sides as much as possible up to the prostate cap-
sule. Among the patients, there were 8 cases with com-
plications of bladder stones, for which first the PVP
surgery was conducted and then pneumatic lithotripsy
(EMS) was conducted, and an Eric flushing device
[Hangzhou Tonglu medical optical instrument factory]
sucked out the bladder stone remnants. After the oper-
ation a three cavity balloon urinary catheter was left to
indwell, and a decision was made about whether or not
to perform bladder irrigation based on observations of
the patient’s urine drainage.
Observation index
The parameters that we assessed chiefly included the
surgical operating time, amount of energy consumed,
changes in the postoperative hemoglobin and serum
sodium, was there urethral catheterization or not,
hospitalization time and early complications during and
after the operation. The patient follow up visit times
were 1, 3, 6 and 12 months after the operation, and then
once annually thereafter. In addition to recording the
occurrence of adverse events, the follow up visit con-
tents also included the maximum urine flow rate
(Qmax), residual urine volume (RUV) and postoperative
PSA changes. During the course of follow-up, filling in
the PISS [sic] score sheets for all of the patients was re-
quired. In addition, we arranged the prostates with dif-
fering sizes in groups (smaller than 80 ml, larger than
80 ml), and thereby assessed the surgical effects based
on prostate size and the symptom alleviation time.
Statistic analysis
All of the data were indicated as the average number +
standard deviation (SD), SPSS 15.0 was used for the
statistical analysis, and a comparative analysis between
three groups or even more groups was done with a
Kruskal-Wallis-H test. A Wilcoxon test was done for theTable 1 Analysis of perioperative parameters before PVP surg
Number of patients Age (year)
Prostate Volume 40 78.6
Smaller than 80 ml
Prostate Volume 80 84.9
Larger than 80 ml
Not anti-coagulant 84 81.1
Anti-coagulant 36 86.6
No Indwelling Catheter 100 82.1
Indwelling Catheter 20 86.06(IPSS, Qmax, Vres and PSA) statistical analyses within
the different groups. A chi-square test was employed for
the comparative analysis of complications. P < 0.05 was
regarded as statistical significance.
Results
Basic conditions of patients
From January 2009 to January 2011, PVP surgery was
conducted on 120 patients with a 120 watt green
laser. Table 1 shows the basic patient data. Of all the
patients, 30% took an oral anti-coagulant drug (aspirin,
Clopidogrel, coumarin derivatives). There were 88 cases
with abnormal ECGs for the complications and 1–8 in-
ternal diseases as the concomitant illnesses, and the
average number of complications was 3.7 internal dis-
eases. Of these, there were 42 cases of cardiovascular
disease, 56 cases of hypertension, 51 cases of respiratory
system diseases, 39 cases of cerebrovascular diseases, 24
cases of anemia, 16 cases of liver or kidney dysfunction,
18 cases of diabetes and 15 cases of hypoproteinemia.
There were 8 cases of patients with simultaneous
bladder stones, and some of the patients had as compli-
cations fever, hypovolemia, acid–base imbalance and
hyperlipidemia, etc. There were no significant differ-
ences between the ages and PSA levels among the pa-
tients with differing prostate sizes in the two groups.
Perioperative data
The amount of energy consumed during the operation and
the prostate volume were clearly correlated (P < 0.001), the
average indwelling catheter time for all patients was 1.67 ±
1.2 days, and the average hospitalization time was 4.67 ±
2.9 days.
Recovery of functions
The average follow-up time was 20.8 ± 3.2 (18–24)
months. After the urinary catheter was removed, the
urination symptoms of the majority of patients was re-
markably improved compared to those before the sur-
gery, and during the follow-up period of up to 2 years
there was a marked improvement in all the patients’ery was performed on 120 Patients
IPSS Qmax (ml/s) PVR (ml) Prostate volume (ml)
25.6 7.6 249.5 25.1
26.95 5.5 362.2 86.6
26.4 7.5 256.2 66.5
26.7 3.1 260.7 35.1
25.9 7.44 156.5 61.6
29.5 NR 719.0 88.6
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marked distinction in the maximum urinary flow rate
test for each group of patients with different prostate
sizes (Table 2).
Analysis of complications
The surgical complications may be classified as three
kinds, the complications during surgery, early postopera-
tive complications (within 12 weeks after surgery) and
those during the follow-up period. Table 3 shows a sum-
mary of the complications during the 24-month follow-
up period after surgery for prostates of differing sizes.
Analysis of complications during surgery
No serious complications during surgery manifested
themselves during the surgical period. None of the
patients manifested hyponatremia or any expression of
excess fluid absorption during surgery. No major hemor-
rhaging or recurrent bleeding was observed either dur-
ing the surgery or postoperatively, and no instances of
blood transfusion occurred. The bleeding was relatively
great in 12 patients (10%) during the course of the sur-
gery, and unclear vision manifested itself during the
course of the surgery and the operation time was pro-
longed, but none of the patients suffered any serious
complications postoperatively. In 12 patients (10%) it
was necessary to carry out vaporization with 2 or more
optical fibers since the optical fiber was damaged and
the prostate volume was too large.
Early postoperative complications
Mild hematuria manifested itself in 35 patients (29.2%)
postoperatively, so bladder irrigation was conducted. Of
these, there were 68.5% who were currently taking an
oral anti-coagulant drug. Acute renal failure occurred in
1 case (0.83%) on Day 1 after the operation, and it was
necessary to carry out hemodialysis, and the patient’s
renal function completely recovered within 1 monthTable 2 Analysis of perioperative parameters for prostates VP
Basic parameters Prostate volum
Smaller than 80 ml
Surgery time 61.59 ± 19.2 (20–100)
Amount of energy consumed 111 ± 77 (31–550)
Indwelling catheter time 1.6 ± 0.8 (1–4)
Hospitalization time 2.8 ± 1.8 (1–6)
Hemoglobin test (g/d)
Preoperative 12.6 ± 2.1
Postoperative 12.1 ± 3.4
Serum creatinine (mmol/L)
Preoperative 124 ± 3.8
Postoperative 123 ± 3.1after the operation. The incidence of postoperative dys-
uria was approximately 15% (18 cases).
Follow up
During the 24-month follow up period, we observed 4
patients (3.3%) for whom we needed to carry out
vaporization treatment another time. The incidence of
urethral stricture was 0.8% (1/120), and the incidence
of bladder neck contracture was approximately 1.7%
(2/120), where in the incidence in patients whose pros-
tate volume was relatively small was higher (P < 0.05).
The incidence of stress urinary incontinence was ap-
proximately 2.5% (3/120), and the patients’ ages were all
greater than 80 years old.
Discussion
TURP was the gold standard of BPH operation, it’s
efficiency and safety had been confirmed clinically.
Cleynenbreugel et al. [9] compared four prospective
studies with PVP with TURP. The outcome parameters
of the two methods were no significant difference [10].
But, compared with PVP, patients undergoing TURP ex-
perienced more severe adverse effects. Al-Ansari [11]
first used RCT comparing 120-W PVP versus TURP
with a long-term follow-up of 36 mo. they found that
20% of patients in the TURP group developed significant
bleeding, confirming that bleeding is a major complica-
tion after TURP and often requiring transfusion.
Patients who are on oral anticoagulant therapy have a
high complication rate with a transfusion rate of 30%
when performing conventional TURP [12]. But the PVP
laser causes very little bleeding, so it can be used suc-
cessfully in patients on anticoagulant therapy [13,14]. In
my study, although 30% of the patients took an oral
anti-coagulant drug, no major hemorrhaging or recur-
rent bleeding was observed either during the surgery or
postoperatively, and no instances of blood transfusion




Larger than 80 ml
86.0 ± 36.4 (50–150) 76.4 ± 25.7 (20–150) <0.001
265 ± 85 (120–596) 224 ± 85 (31–596) <0.001
1.7 ± 1.0 (1–5) 1.67 ± 1.2 (1–5) Ns
3.5 ± 2.2 (1–10) 4.67 ± 2.9 (1–10) <0.01
11.8 ± 3.5 12.06 ± 2.1 Ns
11.2 ± 3.2 11.5 ± 1.2 Ns
126 ± 3.6 125 ± 2.8 Ns
121 ± 3.4 122 ± 3.2 Ns
Table 3 Analysis of perioperative complications










(< 80 ml) N (%)
Prostate volume









1 (1) 0 1 (1.1) 0 1 (2.5) 0
Blood
transfusion
0 0 0 0 0 0
TURP
syndrome
0 0 0 0 0 0
Acute renal
failure
0 1 (5) 0 1 (2.7) 0 1 (1.25)
Bladder
irrigation
5 (5) 9 (45) 6 (7.1) 8 (22.2) 4 (10) 10 (12.5)
Early dysuria
(3–14 days)
11 (11) 7 (35) 13 (15.5) 5 (13.9) 8 (20) 10 (12.5)
Re-
catheterization
1 (1) 1 (5) 1 (1.2) 1 (2.7) 1 (2.5) 1 (1.25)
Urinary tract
infection
3 (3) 2 (10) 3 (3.6) 2 (5.5) 2 (5) 3 (3.75)






0 0 0 0 0 0
Interruption of
urination
1 (1) 1 (5) 1 (1.2) 1 (2.7) 2 (5) 0
Reoperation 2 (2) 2 (10) 3 (3.6) 1 (2.7) 0 3 (3.75)
Urethral
stricture
0 0 0 0 0 0
Bladder neck
contracture
0 0 0 0 0 0
Urinary
incontinence





1 (1) 1 (5) 1 (1.2) 1 (2.7) 2 (5) 0
Reoperation 2 (2) 2 (10) 3 (3.6) 1 (2.7) 1 (2.5) 3 (3.75)
Urethral
stricture
1 (1) 0 1 (1.2) 0 1 (2.5) 0
Bladder neck
contracture
1 (1) 1 (5) 1 (1.2) 1 (2.7) 1 (2.5) 1 (1.25)
Urinary
incontinence





1 (1) 1 (5) 1 (1.2) 1 (2.7) 2 (5) 0
Bladder neck
contracture
2 (2) 2 (10) 3 (3.6) 1 (2.7) 1 (2.5) 3 (3.75)
Urinary
incontinence
1 (1) 0 1 (1.2) 0 1 (2.5) 0
Bladder neck
contracture
1 (1) 1 (5) 1 (1.2) 1 (2.7) 1 (2.5) 1 (1.25)
Urinary
incontinence
2 (2) 1 (5) 1 (1.2) 3 (8.3) 2 (5) 2 (2.5)
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pared with the preoperative levels, none of my clinic’s
patients in the PVP operation developed significant
change in the hemoglobin or sodium levels. This could
be explained by the fact that PVP uses saline as an irri-
gant, thus almost removing the risk of TUR syndrome.
We employed total intravenous anesthesia with a
Proseal laryngeal mask airway (PLMA) for the above-
described elderly patients, and were able to obtain good
anesthetic effects through the method of a drug combin-
ation. The Proseal laryngeal mask airway has the
advantages that it is easy operate, it does not cause
mechanical damage to the vocal cords or trachea, the
stress response is light, and it is possible to maintain
ventilation under conditions of voluntary respiration. It
is beneficial for elderly patients with preoperative com-
plications of hypertension, cardio- and cerebrovascular
diseases and respiratory failure, and its unique double
balloon structure and drain tube structure raise the her-
metical seal quality of the laryngeal mask airway, and
can also extract gastric fluid or gas, and can reduce
complications due to gastric distension and reflux and
mis-aspiration of gastric contents. It also lowered com-
plications such as cardio- and cerebrovascular accidents
caused by abrupt fluctuations in circulation and postop-
erative pulmonary infections [16].
We employed the following methods to handle the fre-
quently observed complications in PVP surgery.
Hemorrhage
Even the PVP laser causes very little bleeding during the
operation. In my clinic’s patients, the bleeding was rela-
tively great in 12 patients (10%) during the course of the
surgery. Hemorrhage during green laser surgery can be
classified in two types, venous hemorrhage and arterial
hemorrhage. Venous hemorrhage chiefly originates in
the squeezing of the urethral mucous membrane and
hemorrhage inside the prostate tissue. The volume of
such hemorrhaging is not very large, but it will have an
effect on the field of view during the course of the oper-
ation, so during the course of insertion of the mirror
sheath insertion is done along the urethra to the max-
imum extent possible, and during the course of the op-
eration the optical fiber is moved as much as possible, in
order to reduce the activity of the mirror sheath from
being able to reduce the generation of bleeding. Atten-
tion is particularly needed at the time of bladder neck
incision, especially since the prostate tissue at this place
hemorrhages easily, so we recommend that the speed
during vaporization be lowered so that it is possible to
reduce hemorrhaging.
Rupture of the artery supplying blood to the prostate
tumor is the chief cause of arterial hemorrhage, and
avoiding the prostate stones during the course of theoperation can reduce the occurrence of this kind of
hemorrhage [16]. If one wishes to control hemorrhage,
the best method is to use 20 watts condensing power to
illuminate the tissue in the area around the hemorrhage
locus, and to make the tissue edema place pressure on
the artery and achieve the goal of hemostasis.
Dysuria
The incidence of postoperative dysuria was approxi-
mately 15% (18 cases) in my clinic’s patients. Compara-
tively speaking, patients whose prostate volume was
smaller have higher proportion of dysuria (P < 0.01), and
ordinarily it was not until 4–6 moths after the surgery
that the symptoms of dysuria could be resolved com-
pletely. The chief causes of postoperative dysuria are a
decline in laser vaporization efficiency, incomplete tissue
vaporization and an excessively high coagulative prostate
proportion, and these are positive correlated with the ex-
tent of a patient’s dysuria. Therefore, during the course
of the operation one should avoid as much as possible
excessive cauterization of the bladder trigone. Since pa-
tients with excessively large prostate medial lobes have
to undergo repeated cauterization and hemostasis during
the operation, this results in chronic inflammation,
fibrosis and calcification of the remaining prostate tissue,
and this raises the risk that dysuria will occur postopera-
tively, and one should consider using Dexamethasone to
alleviate the symptoms in Week 1 after the operation.
Bladder neck contracture
The incidence of bladder neck contracture was approxi-
mately 1.7% (2/120) in my clinic, where the incidence
was higher in patient with smaller prostate (P < 0.05).
When we conducted a comparison of prostates with dif-
ferent volumes, we were able to learn that the incidence
of bladder neck contracture was markedly lower in the
group whose prostate volume was relatively large. Exces-
sive cauterization of the bladder neck may cause bladder
neck contracture [17]. Therefore, during the course of
the operation one should avoid as much as possible ex-
cessive coagulation and laser cauterization. Using the
optical fiber as much as possible at the bladder neck to
replace the entry and exit activity of the mirror sheath
can reduce the damage to the bladder neck. It is neces-
sary to carry out preventively a bladder neck incision
during the course of PVP surgery in order to prevent
contracture from manifesting itself postoperatively.
Urethral stricture
Urethral stricture may cause by the injury of the bulbous
part of the urethra. We carried out the operation with a
22.5 F laser mirror equipped with a single optical fiber
channel, and the incidence of urethral stricture within
1 year after the surgery was only 0.8% (1/120), and there
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pared to previous literature reports. During the course
of inserting the laser mirror sheath, one should try to
the extent possible to achieve entry under direct vision,
and avoid damaging the urethral mucous membrane. It
is also extremely important to carry out preventive
handling if one discovers urethral stricture prior to the
operation. By changing the 26 F mirror sheath that was
initially used to a 22.5 F laser vaporization sheath, it is
possible to markedly reduce the incidence of urethral
stricture. During a randomized comparative study the
22.5 laser sheath and TURP, one can see that there is a
higher probability of urethral stricture occurring in the
TURP operation (6.1% vs. 2.1%).
The reason why the incidence of urethral stricture is
relatively high in patients whose prostate volume is rela-
tively small (< 40 ml) may be that the initial researchers
using PVP usually started from small prostates, and in
order to keep the urinary sphincter from suffering any
damage, when they moved the laser mirror sheath it was
even closer to the bulbous part of the urethra, and this
may have caused damage to the mucous membrane, and
ultimately caused urethral stricture.
Damage to the ureteral opening
There wre only 1 case of patient need hemodialysis after
PVP operation because of damaging the ureteral open-
ing. The chief cause of damage to the ureteral opening is
that the laser beam has irradiated ureteral opening dur-
ing the operation. Therefore, it is extremely important
to check the location of the ureteral opening before the
start of laser vaporization, and the ureteral opening must
be examined again prior to handling the bladder neck
and prostate medial lobes. It is possible to label the ur-
eteral opening beforehand with indigo carmine, and if
the prostate is too large and is placing pressure on the
bladder neck, [the laser beam] suddenly enters the blad-
der and covers the ureteral opening at both sides, and
damage to the ureteral opening will appear easily. There-
fore, it is necessary to set the laser beam position first
before the prostate medial lobes and lateral lobes prior
to vaporization.
Reoperation for patients with large volume prostate
hyperplasia
In my study, there were 4 patients (3.3%) needed to
carry out vaporization treatment another time. The chief
reasons were that the prostate tissue that was vaporized
in the first operation was insufficient and the prostate
tissue grew again. The preoperative prostate volume of
patients who underwent a second operation was rela-
tively large in each case.
Having adequate laser power acting on the prostate is
the key to the therapeutic effects of PVP surgery. Duringthe course of our study, the reoperation rate was ap-
proximately 4% or less, and among our patients the re-
operation rate for patients with larger prostate volume
was higher.
The results of study indicate that the total energy con-
sumption of patients with a relatively large prostate was
relatively high, whereas the average energy per each
millimeter of prostate was relatively low. In addition, the
surgeon’s learning curve may also affect the reoperation
rate. In the course of reviewing the study, one can see
that the reoperation for the first 30 patients was 10%,
while the reoperation rate for the patients after that rap-
idly declined to 0-1%. When it is a prostate with a large
volume, it may be necessary to consume two or more
optical fibers before it is possible to obtain a suitable
urination cavity path. The costs of the surgery increase
for these patients, but PVP surgery reduced each of the
complications of such patients compared with an open
operation, and it is also worth considering such prob-
lems as the prolongation of the hospitalization time, loss
of the ability to work and needing to convalesce for a
relatively long time.Conclusion
PVP surgery was safe and effective. There is little hemor-
rhaging preoperatively and postoperatively, and there
were no cases of blood transfusion. The operation time
was controlled to 150 minutes or less, and it was pos-
sible to improve the various subjective and objective
urination parameters. When it comes to various high
risk patients and patients taking an oral anti-coagulation
drug, 120 watt PVP surgery can minimize hemorrhaging
and various surgery-related risks, reduce complications
like urinary incontinence and urethral stricture, and im-
prove markedly the postoperative urination symptoms.
The results of this study indicate clearly that therapeutic
effects of 120 watt PVP surgery are excellent and the ef-
fects of treatment are good, and are more suitable for
use in high risk patients. Complications are not classified
using a standardized method is the limition of my study.
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